Back to work… Some objectives for 2012

So, after two weeks of holiday (although I have to admit it wasn’t really a vacation – I saw my mother pass away after months of fighting…) I am now back in the office. You may recall my last blog post from 2011, where I summarized 2011 and gave a few ideas on what 2012 will be about, at least regarding CSR and environmental affairs in the pharmaceutical sector. Let me here present some of the objectives for 2012 that I, Pfizer and LIF (the association of the research based pharmaceutical industry in Sweden) have in the field:

My most important objective for the year, in my part-time role at LIF, is to deliver according to the project plan for action item 7.2 in the Swedish National Pharmaceutical Strategy (NLS):

7.2. Encourage voluntary control of emissions from pharmaceutical factories (Lead: LIF): Introduction of a voluntary environmental labeling of pharmaceutical products.

In order for LIF to be succesful in this work it is crucial that Sofia Wallström comes to a positive conclusion regarding green economic incentives in her review including action item 7.1. in the National Pharmaceutical Strategy:

7.1. Investigate if the environmental aspects should be considered when decisions on subsidy for a pharmaceutical are decided (Lead: Ministry of Health and Social Affairs): Review of possibilities to – within the context of the national reimbursement system – increasingly take environmental considerations.

Read more about the environmental action items in the National Pharmaceutical Strategy via this link. Below is my hand-written version of the project plan for item 7.2 that I update continuously as the project develops…

Project plan NLS 7.2

Project plan NLS 7.2

I know it is difficult to see the details of the project plan, but I can tell you that an additional crucial issue (in addition to positive conclusions in Sofia W’s work on NLS 7.1) is the development and finalization of green criteria for pharmaceuticals: Which pharmaceuticals are green? Below is a summary of criteria discussed in LIF’s round-table discussions during 2011:

My second most important objective for 2012 will be to develop a CSR platform for LIF, and to maintain and further develop the CSR-programs in Pfizer. When it comes to a CSR platform for LIF you will find some of parts on which I believe the platform should be based in my blog post from Oct 19, when I wrote about my part-time assignment at LIF. Regarding the CSR programs at Pfizer I recommend that you read about them on our Swedish web site and on our global web site. There are a lot of interesting projects, programs and initiatives running. It is a huge task only to maintain them, even more so to further develop them.

If you have followed me here at the blog you would probably know that one of the more interesting developments of our CSR program I strongly believe in is the ”more-than-medication initiatives”. Please spend some time reviewing our Canadian colleagues’ initiative at or our Australian colleagues’ program at These kinds of initiatives are extremely important in what I refer to as Step 1, in our model called ”4 steps to a sustainable use of pharmaceuticals”:

Sustainable use of pharmaceuticals

Sustainable use of pharmaceuticals

Let’s hope for a productive and successful 2012!


E-postadressen publiceras inte. Obligatoriska fält är märkta *